• Evaluation of iNstroke Aspiration Catheters for Thrombectomy: a Multi-center Prospective Study

  NCT07376447

  Not yet recruitingInterventionalNot ApplicableUpdated Feb 2, 2026
• Efficacy and Safety Evaluation of the Thromboaspiration Catheter System iNstroke in Patients With Acute Ischemic Stroke

  NCT05720975

  CompletedObservationalUpdated May 9, 2025
• Safety and Efficacy Evaluation of the iNstroke 4F Thromboaspiration Catheter in Patients With Acute Ischaemic Stroke Due to Primary Distal Medium Vessel Occlusions (DMVO)

  NCT07357285

  RecruitingInterventionalNot ApplicableUpdated Jan 23, 2026
• Safety and Efficacy of Intracranial Thrombus Aspiration Catheter in the Treatment of Acute Large-vessel Occlusive Stroke

  NCT05101668

  TerminatedInterventionalNot ApplicableUpdated Apr 27, 2023
• Prospective, Multicentre Study to Evaluate the Thrombectomy System for Stroke: iNedit, iNdeep and iNtercept

  NCT05893719

  CompletedObservationalUpdated May 16, 2025
• ANAIS Study to Confirm the Safety and Performance of the ANA 5F Advanced Neurovascular Access®

  NCT05409430

  CompletedInterventionalNot ApplicableUpdated Jul 20, 2023

ClinicalTrials.gov ID

NCT07571954

Lead Sponsor

iVascular S.L.U.INDUSTRY

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Not Applicable

Enrollment

45Estimated

Last Update Posted

May 13, 2026Actual

Start Date

Aug 31, 2026Estimated

Primary Completion Date

Jul 31, 2027Estimated

Completion Date

Nov 30, 2027Estimated

Official Title

Prospective, Single-arm, Multi-centre Study to Evaluate the Efficacy and Safety of the Instroke 5F Thromboaspiration Catheter in Patients With Acute Ischaemic Stroke.

Brief Summary

Prospective, single-arm, multi-centre study to evaluate the efficacy and safety of the iNstroke 5F thromboaspiration catheter in patients with acute ischaemic stroke

Detailed Description

This clinical investigation has been designed to evaluate the efficacy and safety of the iNstroke 5F aspiration catheter for its use in the treatment of LVO, with a view to comparing this product with standard therapy or with other similar products in a future pivotal clinical investigation.

• Acute Ischemic Stroke

• Thromboaspiration catheter

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Subjects aged ≥ 18 years.
• Subjects able to be treated (i.e., defined by groin puncture time) within 24 hours of symptom onset or last time seen well.
• Occlusion in a large or proximal medium vessel (M1, proximal M2, A2 or P2) identified by magnetic resonance angiography (MRA) or computed tomography angiography (CTA).
• Baseline NIHSS score ≥ 6 assessed before the procedure.
• Pre-stroke mRS score ≤ 2.
• Subjects with an ASPECTS score ≥ 6.
• Informed consent obtained in accordance with the applicable country-specific regulations and as approved by the Ethics Committee (EC).
• France-specific inclusion criteria: As applicable under French law, subjects affiliated with a health social security scheme or equivalent.

Exclusion Criteria:

• Severe comorbidity and/or shortened life expectancy that will likely prevent improvement or follow up or that will render the procedure unlikely to benefit the patient.
• Severe allergy to contrast media.
• Women of child-bearing potential.
• Subjects with intracranial atherosclerotic occlusive disease or extra- or intracranial dissection.
• Medical history of thrombocytopenia (Platelets <100,000).
• Subjects with tandem occlusions (evidence of complete occlusion, high-grade stenosis or arterial dissection in the extracranial or petrous segment of the internal carotid artery).
• Subjects with occlusions in multiple vessels.
• Subjects with cancer who have a life expectancy of less than 6 months.
• Pre-existing neurological or psychiatric illness that could confound the neurological or functional assessments.
• Severe sustained hypertension (systolic pressure >185 mm Hg or diastolic pressure >110 mm Hg). Note: If blood pressure can be successfully reduced and maintained at an acceptable level by administering the medication recommended by the ESO (European Stroke Organisation) in its guidelines (also IV infusion of antihypertensives), the subject may be included.
• Known or suspected cerebral vasculitis.
• Known renal insufficiency with creatinine ≥3 mg/dl or Glomerular Filtration Rate (GFR) <30 mL/min.
• Current participation in an interventional drug or device study that may confound the results of this study.
• Intracranial stenosis proximal to the occlusion.
• France-specific exclusion criteria: As applicable under French law, breastfeeding women, persons deprived of their liberty by a judicial or administrative decision, or persons of legal age who are the subject of a legal protection measure.

Primary Purpose

Treatment

Allocation

N/A

Interventional Model

Single Group Assignment

Masking

None (Open Label)

Lead Sponsor

iVascular S.L.U.INDUSTRY

clinica@ivascular.global+34 936724711

clinica@ivascular.global+34 936724711

clinica@ivascular.global+34 936724711

clinica@ivascular.global+34 936724711